Christine M Cheng

Summary

Affiliation: University of California
Country: USA

Publications

  1. doi request reprint Boxed warning inconsistencies between drug information resources and the prescribing information
    Christine M Cheng
    Department of Clinical Pharmacy, Medication Outcomes Center, University of California, San Francisco, 94143 0622, USA
    Am J Health Syst Pharm 68:1626-31. 2011
  2. doi request reprint Hospital systems for the detection and prevention of adverse drug events
    C M Cheng
    Medication Outcomes Center, Department of Clinical Pharmacy, University of California, San Francisco, San Francisco, California, USA
    Clin Pharmacol Ther 89:779-81. 2011
  3. pmc Cosmetic use of botulinum toxin type A in the elderly
    Christine M Cheng
    Department of Clinical Pharmacy, University of California, San Francisco, CA 94143 0622, USA
    Clin Interv Aging 2:81-3. 2007
  4. ncbi request reprint Unlabeled uses of botulinum toxins: a review, part 2
    Christine M Cheng
    University of California at San Francisco, San Francisco, CA 94143, USA
    Am J Health Syst Pharm 63:225-32. 2006
  5. ncbi request reprint Unlabeled uses of botulinum toxins: a review, part 1
    Christine M Cheng
    Drug Information and Analysis Service, University of California at San Francisco, San Francisco, CA 94143, USA
    Am J Health Syst Pharm 63:145-52. 2006
  6. ncbi request reprint Intrathecal ziconotide for refractory chronic pain
    Shalini S Lynch
    Department of Clinical Pharmacy, University of California, San Francisco, 94143, USA
    Ann Pharmacother 40:1293-300. 2006
  7. ncbi request reprint Bevacizumab for neovascular ocular diseases
    Shalini S Lynch
    Department of Clinical Pharmacy, University of California, San Francisco, CA 94143, USA
    Ann Pharmacother 41:614-25. 2007
  8. doi request reprint A review of three stand-alone topical thrombins for surgical hemostasis
    Christine M Cheng
    School of Pharmacy, University of California San Francisco, San Francisco, California, USA
    Clin Ther 31:32-41. 2009
  9. ncbi request reprint Simple additions to the pharmacy waiting area may increase patient satisfaction
    Christine M Cheng
    Kaiser Permanente Medical Center, Santa Clara, Calif, USA
    J Am Pharm Assoc (2003) 44:630-2. 2004
  10. doi request reprint The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond?
    Carla Meyer-Massetti
    Department of Clinical Pharmacy, School of Pharmacy, University of California San Francisco, Medication Outcomes Center, San Francisco, California, USA
    J Hosp Med 5:E8-16. 2010

Collaborators

Detail Information

Publications11

  1. doi request reprint Boxed warning inconsistencies between drug information resources and the prescribing information
    Christine M Cheng
    Department of Clinical Pharmacy, Medication Outcomes Center, University of California, San Francisco, 94143 0622, USA
    Am J Health Syst Pharm 68:1626-31. 2011
    ..Inconsistencies in boxed warnings between drug information resources and the manufacturer's prescribing information (PI) were evaluated...
  2. doi request reprint Hospital systems for the detection and prevention of adverse drug events
    C M Cheng
    Medication Outcomes Center, Department of Clinical Pharmacy, University of California, San Francisco, San Francisco, California, USA
    Clin Pharmacol Ther 89:779-81. 2011
    ..Many technologies have emerged in recent years to reduce ADEs at various points in the medication use process; however, interfacing some of these key technologies with existing hospital systems poses significant challenges...
  3. pmc Cosmetic use of botulinum toxin type A in the elderly
    Christine M Cheng
    Department of Clinical Pharmacy, University of California, San Francisco, CA 94143 0622, USA
    Clin Interv Aging 2:81-3. 2007
    ....
  4. ncbi request reprint Unlabeled uses of botulinum toxins: a review, part 2
    Christine M Cheng
    University of California at San Francisco, San Francisco, CA 94143, USA
    Am J Health Syst Pharm 63:225-32. 2006
    ..Efficacy and safety data regarding the unlabeled uses of botulinum toxins are reviewed, and the pharmacology, adverse effects, and characteristics of commercially available botulinum toxins are discussed...
  5. ncbi request reprint Unlabeled uses of botulinum toxins: a review, part 1
    Christine M Cheng
    Drug Information and Analysis Service, University of California at San Francisco, San Francisco, CA 94143, USA
    Am J Health Syst Pharm 63:145-52. 2006
    ..Efficacy and safety data regarding the unlabeled uses of botulinum toxins are reviewed, and the pharmacology, adverse effects, and characteristics of commercially available botulinum toxins are discussed...
  6. ncbi request reprint Intrathecal ziconotide for refractory chronic pain
    Shalini S Lynch
    Department of Clinical Pharmacy, University of California, San Francisco, 94143, USA
    Ann Pharmacother 40:1293-300. 2006
    ..To describe the pharmacology, efficacy, and safety of ziconotide for treatment of severe chronic pain in patients who are candidates for intrathecal therapy...
  7. ncbi request reprint Bevacizumab for neovascular ocular diseases
    Shalini S Lynch
    Department of Clinical Pharmacy, University of California, San Francisco, CA 94143, USA
    Ann Pharmacother 41:614-25. 2007
    ..To review the efficacy and safety of off-label use of bevacizumab for neovascular ocular diseases...
  8. doi request reprint A review of three stand-alone topical thrombins for surgical hemostasis
    Christine M Cheng
    School of Pharmacy, University of California San Francisco, San Francisco, California, USA
    Clin Ther 31:32-41. 2009
    ..The 3 active topical thrombins that are currently marketed are bovine plasma-derived thrombin, human plasma-derived thrombin, and human recombinant thrombin...
  9. ncbi request reprint Simple additions to the pharmacy waiting area may increase patient satisfaction
    Christine M Cheng
    Kaiser Permanente Medical Center, Santa Clara, Calif, USA
    J Am Pharm Assoc (2003) 44:630-2. 2004
  10. doi request reprint The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond?
    Carla Meyer-Massetti
    Department of Clinical Pharmacy, School of Pharmacy, University of California San Francisco, Medication Outcomes Center, San Francisco, California, USA
    J Hosp Med 5:E8-16. 2010
    ..We reviewed the evidence for the FDA warning and provide a potential medical center response to this warning...
  11. doi request reprint Black box warning contraindicated comedications: concordance among three major drug interaction screening programs
    Lorraine M Wang
    San Francisco Veterans Administration Medical Center, San Francisco, CA, USA
    Ann Pharmacother 44:28-34. 2010
    ..Some black box warnings recommend against coadministration of specific medications due to an increased risk for serious, perhaps life-threatening, effects...